For research use only. Not for therapeutic Use.
Ritlecitinib tosylate（Cat No.:I035600）is a selective Janus kinase (JAK) family and TEC kinase inhibitor under investigation for the treatment of autoimmune diseases, such as alopecia areata and rheumatoid arthritis. By targeting specific kinases involved in immune signaling, ritlecitinib suppresses overactive immune responses that lead to inflammation and tissue damage. Its dual action on JAK and TEC kinases helps to modulate immune activity more precisely, potentially reducing the side effects associated with broader JAK inhibition. Ritlecitinib tosylate shows promise in clinical trials as a novel therapeutic for immune-mediated disorders.
| Catalog Number | I035600 |
| CAS Number | 2192215-81-7 |
| Synonyms | 4-methylbenzenesulfonic acid;1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one |
| Molecular Formula | C22H27N5O4S |
| Purity | 98% |
| Target | JAK3/TEC |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | 4-methylbenzenesulfonic acid;1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one |
| InChI | InChI=1S/C15H19N5O.C7H8O3S/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15;1-6-2-4-7(5-3-6)11(8,9)10/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19);2-5H,1H3,(H,8,9,10)/t10-,11+;/m0./s1 |
| InChIKey | YOZLVAFWYLSRRN-VZXYPILPSA-N |
| SMILES | C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3.CC1=CC=C(C=C1)S(=O)(=O)O |
| Reference | [1]. Telliez JB, et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12):3442-3451. |
